Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Molecular imaging of brain amyloid in mild cognitive impairment and Alzheimer's disease

Nature Clinical Practice Neurology volume 3, pages 366–367 (2007)Cite this article

boxed-textSmall GW et al. (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652–2663

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Petersen RC et al. (2001) Current concepts in mild cognitive impairment. Arch Neurol 58: 1985–1992

    Article  CAS  Google Scholar 

  2. Cummings JL (2004) Alzheimer's Disease. New Engl J Med 351: 56–67

    Article  CAS  Google Scholar 

  3. Lockhart A (2006) Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov Today 11: 1093–1099

    Article  CAS  Google Scholar 

  4. Kantarci K and Jack CR Jr (2003) Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 13: 197–209

    Article  Google Scholar 

  5. Engler H et al. (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129: 2856–2866

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. GSK Clinical Imaging Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK paul.m.matthews@gsk.com

Authors and Affiliations

  1. PM Matthews is Vice-President for Imaging, Genetics and Neurology at GlaxoSmithKline and Head of the GSK Clinical Imaging Centre, Hammersmith Hospital, London, UK.,

    Paul M Matthews

Authors
  1. Paul M Matthews
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Paul M Matthews is employed by GlaxoSmithKline, which is developing therapies for Alzheimer's disease that should have applications in people with mild cognitive impairment. GlaxoSmithKline is closely collaborating with Siemens in aspects of molecular imaging.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matthews, P. Molecular imaging of brain amyloid in mild cognitive impairment and Alzheimer's disease. Nat Rev Neurol 3, 366–367 (2007). https://doi.org/10.1038/ncpneuro0520

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0520

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing